Dermatomyositis Drug Pipeline Analysis Report 2025

Dermatomyositis is a rare autoimmune disease causing muscle weakness and skin rashes. It accounts for approximately 1.2 to 21 cases per 100,000 people, with incidence estimates ranging from 1.0 to 15 per million. The demand for better therapies is rising due to limited treatment options. There is a growing focus on advanced dermatomyositis therapeutics, including biologics and immunomodulators. Recent developments, such as novel drug candidates targeting inflammatory pathways, are driving market growth. With increasing research and clinical trials, the dermatomyositis drug pipeline is expected to expand significantly in the coming years, improving patient outcomes and treatment efficacy.

Report Coverage

The Dermatomyositis Drug Pipeline Insight Report by the publisher gives comprehensive insights into dermatomyositis therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for dermatomyositis. The dermatomyositis report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The dermatomyositis pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with dermatomyositis treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to dermatomyositis.

Dermatomyositis Drug Pipeline Outlook

Dermatomyositis is a rare inflammatory disease affecting the muscles and skin. It occurs due to an abnormal immune response, leading to muscle weakness and a distinctive skin rash. The exact cause is unknown but may involve genetic, environmental, or autoimmune factors. It can affect individuals of any age, with symptoms ranging from fatigue to difficulty swallowing.

Dermatomyositis treatments focus on reducing inflammation and managing symptoms. Common therapies include corticosteroids, immunosuppressive drugs, and intravenous immunoglobulin (IVIG). Physical therapy helps maintain muscle strength. Emerging treatments, such as biologics and targeted immunotherapies, aim to improve outcomes and reduce disease progression.

Dermatomyositis Epidemiology

The dermatomyositis drug pipeline is expanding due to rising disease incidence and ongoing clinical research. Current dermatomyositis incidence estimates range from 1.0 to 15 per million, with prevalence ranging from 1.2 to 21 per 100,000. In the United States, approximately 2,858 new dermatomyositis cases occur annually, with a higher incidence among females. Juvenile dermatomyositis affects 500-1,000 children in the United Kingdom and Ireland.

Dermatomyositis - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of dermatomyositis drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Gene Therapy
• Cell-based Therapies
• Nucleic Acid Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Dermatomyositis - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total dermatomyositis clinical trials.

Dermatomyositis - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the dermatomyositis pipeline analysis include small molecules, biologics, gene therapy, cell-based therapies, and nucleic acid therapies. The dermatomyositis report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for dermatomyositis.

Dermatomyositis Clinical Trials Therapeutic Assessment - Competitive Dynamics

The report for the dermatomyositis drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed dermatomyositis therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Dermatomyositis clinical trials:

• AstraZeneca
• Pfizer
• Chongqing Precision Biotech Co., Ltd.
• Priovant Therapeutics, Inc.
• Galapagos NV
• Argenx
• EMD Serono Research & Development Institute, Inc.
• Immunoforge Co. Ltd.
• Amgen
• Chugai Pharmaceutical
• Merck KGaA

Dermatomyositis Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for dermatomyositis. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of dermatomyositis drug candidates.

Drug: Brepocitinib

Brepocitinib is a dual selective TYK2/JAK1 inhibitor administered orally once daily. The drug candidate is undergoing a Phase III, randomized, placebo-controlled clinical trial, which is sponsored by Priovant Therapeutics, Inc. The study aims to evaluate the efficacy and safety of brepocitinib in adults with dermatomyositis. It measures differences in the total improvement score (TIS) over 52 weeks, followed by an optional 52-week open-label extension phase.

Drug: M5049 High Dose

M5049, developed by EMD Serono Research & Development Institute, Inc., is an orally administered small molecule dual TLR7 and TLR8 antagonist targeting immune system dysfunction. It is a part of a Phase II study (NEPTUNIA) that aims to evaluate the efficacy and safety of Enpatoran in 40 participants with dermatomyositis (DM) and polymyositis (PM) over 24 weeks. The study is estimated to be completed by April 2025.

Reasons To Buy This Report

The Dermatomyositis Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for dermatomyositis. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into dermatomyositis collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Dermatomyositis - Pipeline Insight Report

• Which companies/institutions are leading the dermatomyositis drug development?
• What is the efficacy and safety profile of dermatomyositis pipeline drugs?
• Which company is leading the dermatomyositis pipeline development activities?
• What is the current dermatomyositis commercial assessment?
• What are the opportunities and challenges present in the dermatomyositis drug pipeline landscape?
• What is the efficacy and safety profile of dermatomyositis pipeline drugs?
• Which company is conducting major trials for dermatomyositis drugs?
• Which companies/institutions are involved in dermatomyositis collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in dermatomyositis?

This product will be delivered within 3-5 business days.